The humoral immune response is a mechanism that potently suppresses or prevents viral infections. However, genetic diversity and resistance to antibody-mediated neutralization are serious obstacles in controlling HIV-1 infection. In this study, we isolated monoclonal antibodies from an SIV-infected macaque by using the phage display method to characterize antibodies in SIV infection. Variable regions of immunoglobulin genes were amplified by rhesus macaque-specific primers and inserted into the phagemid pComb3X, which produced the Fab fragment. Antibodies against SIV proteins were selected by biopanning using an SIV protein-coated 96-well plate. A total of 20 Fab clones obtained included 14 clones directed to gp41, four clones to gp120, and two clones to p27. The anti-gp120 Fab clones completely neutralized the homologous neutralization-sensitive SIVsmH635FC and the genetically divergent SIVmac316, and showed at least 50% inhibition against the neutralization-resistant strain, SIVsmE543-3. Competition ELISA revealed that these anti-gp120 Fab clones recognize the same epitope on gp120 including the V3 loop. Identification of antibodies with potent neutralizing activity will help to elucidate the mechanisms for inducing broadly neutralizing antibodies.
Get full access to this article
View all access options for this article.
References
1.
IgarashiT, BrownC, AzadeganAet al.Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med, 1999; 5,2:211–216.
2.
ShibataR, IgarashiT, HaigwoodNet al.Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med, 1999; 5,2:204–210.
3.
VeazeyRS, ShattockRJ, PopeMet al.Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med, 2003; 9,3:343–346.
4.
HessellAJ, RakaszEG, PoignardPet al.Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog, 2009; 5,5:e1000433.
5.
MascolaJR, StieglerG, VanCottTCet al.Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med, 2000; 6,2:207–210.
6.
D'SouzaMP, LivnatD, BradacJA, BridgesSH. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. J Infect Dis, 1997; 175,5:1056–1062.
7.
WalkerLM, PhogatSK, Chan-HuiPYet al.Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science, 2009; 326,5950:285–289.
8.
SaphireEO, ParrenPW, PantophletRet al.Crystal structure of a neutralizing human IGG against HIV-1: A template for vaccine design. Science, 2001; 293,5532:1155–1159.
9.
Karlsson HedestamGB, FouchierRA, PhogatS, BurtonDR, SodroskiJ, WyattRT. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol, 2008; 6,2:143–155.
10.
LiY, MiguelesSA, WelcherBet al.Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med, 2007; 13,9:1032–1034.
11.
HaynesBF, FlemingJ, St ClairEWet al.Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science, 2005; 308,5730:1906–1908.
12.
OfekG, McKeeK, YangYet al.Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol, 2010; 84,6:2955–2962.
13.
PoignardP, SaphireEO, ParrenPW, BurtonDR. gp120: Biologic aspects of structural features. Annu Rev Immunol, 2001; 19:253–274.
14.
HirschVM, LifsonJD. Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. Adv Pharmacol, 2000; 49:437–477.
JohnsonWE, SanfordH, SchwallLet al.Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol, 2003; 77,18:9993–10003.
17.
MeansRE, MatthewsT, HoxieJA, MalimMH, KodamaT, DesrosiersRC. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: Correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4. J Virol, 2001; 75,8:3903–3915.
ChassagneS, LafflyE, DrouetE, HerodinF, LefrancMP, ThullierP. A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library. Mol Immunol, 2004; 41,5:539–546.
20.
GlamannJ, BurtonDR, ParrenPWet al.Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: Recovery from a long-term-nonprogressor SIV-infected macaque. J Virol, 1998; 72,1:585–592.
21.
DruarC, SainiSS, CossittMAet al.Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus' soluble glycoprotein. Immunogenetics, 2005; 57,10:730–738.
22.
ColeKS, AlvarezM, ElliottDHet al.Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. Virology 10, 2001; 290,1:59–73.
23.
RobinsonJE, ColeKS, ElliottDHet al.Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine. AIDS Res Hum Retroviruses, 1998; 14,14:1253–1262.
24.
LussoP, CocchiF, BalottaCet al.Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol, 1995; 69,6:3712–3720.
25.
TakeuchiY, McClureMO, PizzatoM. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol, 2008; 82,24:12585–12588.
26.
WeiX, DeckerJM, LiuHet al.Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother, 2002; 46,6:1896–1905.
27.
DerdeynCA, DeckerJM, SfakianosJNet al.Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol, 2000; 74,18:8358–8367.
28.
PlattEJ, WehrlyK, KuhmannSE, ChesebroB, KabatD. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol, 1998; 72,4:2855–2864.
29.
MornerA, BjorndalA, AlbertJet al.Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol, 1999; 73,3:2343–2349.
30.
DuBridgeRB, TangP, HsiaHC, LeongPM, MillerJH, CalosMP. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol, 1987; 7,1:379–387.
31.
KuwataT, ByrumR, WhittedSet al.A rapid progressor-specific variant clone of simian immunodeficiency virus replicates efficiently in vivo only in the absence of immune responses. J Virol, 2007; 81,17:8891–8904.
32.
KuwataT, DehghaniH, BrownCRet al.Infectious molecular clones from a simian immunodeficiency virus-infected rapid-progressor (RP) macaque: Evidence of differential selection of RP-specific envelope mutations in vitro and in vivo. J Virol, 2006; 80,3:1463–1475.
33.
KuwataT, NishimuraY, WhittedSet al.Association of progressive CD4(+) T cell decline in SIV infection with the induction of autoreactive antibodies. PLoS Pathog, 2009; 5,4:e1000372.
34.
KestlerH, KodamaT, RinglerDet al.Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science, 1990; 248,4959:1109–1112.
35.
MoriK, RinglerDJ, KodamaT, DesrosiersRC. Complex determinants of macrophage tropism in env of simian immunodeficiency virus. J Virol, 1992; 66,4:2067–2075.
36.
ShibataR, MiuraT, HayamiMet al.Mutational analysis of the human immunodeficiency virus type 2 (HIV-2) genome in relation to HIV-1 and simian immunodeficiency virus SIV (AGM)J Virol, 1990; 64,2:742–747.
37.
BarbasCF, ScottJM, SilvermanG, BurtonDR. Phage Display: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2001.
38.
RobinsonJE, HoltonD, LiuJ, McMurdoH, MurcianoA, GohdR. A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A. J Immunol Methods, 1990; 132,1:63–71.
39.
KentKA, GritzL, StallardGet al.Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. AIDS, 1991; 5,7:829–836.
40.
KentKA, RudE, CorcoranTet al.Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res Hum Retroviruses, 1992; 8,6:1147–1151.
41.
LefrancMP, GiudicelliV, GinestouxCet al.IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res, 2009; 37,Database issue:D1006–1012.
42.
OurmanovI, KuwataT, GoekenRet al.Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody. J Virol, 2009; 83,11:5388–5400.
43.
AndrisJS, MillerAB, AbrahamSRet al.Variable region gene segment utilization in rhesus monkey hybridomas producing human red blood cell-specific antibodies: Predominance of the VH4 family but not VH4-21 (V4-34)Mol Immunol, 1997; 34,3:237–253.
44.
BibleJM, HowardW, RobbinsH, Dunn-WaltersDK. IGHV1, IGHV5 and IGHV7 subgroup genes in the rhesus macaque. Immunogenetics, 2003; 54,12:867–873.
45.
ErmertK, MitlohnerH, SchemppW, ZachauHG. The immunoglobulin kappa locus of primates. Genomics, 1995; 25,3:623–629.
46.
HelmuthEF, LetvinNL, MargolinDH. Germline repertoire of the immunoglobulin V(H)3 family in rhesus monkeys. Immunogenetics, 2000; 51,7:519–527.
47.
HowardWA, BibleJM, Finlay-DijsselbloemE, OpenshawS, Dunn-WaltersDK. Immunoglobulin light-chain genes in the rhesus macaque I: Kappa light-chain germline sequences for subgroups IGKV1, IGKV and IGKV3. Immunogenetics, 2005; 57,3–4:210–218.
48.
HowardWA, BibleJM, Finlay-DijsselbloemE, OpenshawS, Dunn-WaltersDK. Immunoglobulin light-chain genes in the rhesus macaque II: Lambda light-chain germline sequences for subgroups IGLV1, IGLV2, IGLV3, IGLV4 and IGLV5. Immunogenetics, 2005; 57,9:655–664.
49.
LinkJM, HellingerMA, SchroederHWJr. The rhesus monkey immunoglobulin IGHD and IGHJ germline repertoire. Immunogenetics, 2002; 54,4:240–250.
50.
LinkJM, LarsonJE, SchroederHW. Despite extensive similarity in germline DH and JH sequence, the adult rhesus macaque CDR-H3 repertoire differs from human. Mol Immunol, 2005; 42,8:943–955.
51.
ScinicarielloF, EnglemanCN, JayashankarL, McClureHM, AttanasioR. Rhesus macaque antibody molecules: Sequences and heterogeneity of alpha and gamma constant regions. Immunology, 2004; 111,1:66–74.
52.
GibbsRA, RogersJ, KatzeMGet al.Evolutionary and biomedical insights from the rhesus macaque genome. Science, 2007; 316,5822:222–234.
